SCHEMBL3007269

SCHEMBL3007269

COc1ccccc1-c1csc(N2CCC(S(=O)(=O)c3ccc(Br)cc3)CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.46
SMN1; SMN2 Q16637 6/20 0.43
RAB9A P51151 5/20 0.43
KMT2A Q03164 4/20 0.43
NPC1 O15118 3/20 0.43
MEN1 O00255 3/20 0.43
MAPT P10636 3/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
CYP2C19 P33261 1/20 0.42
USP2 O75604 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM1A O60341 1/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
UCHL1 P09936 1/20 0.39
USP30 Q70CQ3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011242 0.91 AR (0.47) ARSMN1; SMN2RAB9AKMT2ANPC1
SCHEMBL3010419 0.91 MAPT (0.52) ARSMN1; SMN2RAB9AKMT2ANPC1
SCHEMBL3016521 0.91 AR (0.54) ARSMN1; SMN2RAB9AKMT2ANPC1
SCHEMBL3010988 0.90 AR (0.46) ARSMN1; SMN2RAB9AKMT2ANPC1
SCHEMBL3017766 0.90 AR (0.44) ARSMN1; SMN2RAB9AKMT2ANPC1
SCHEMBL3017184 0.90 AR (0.46) ARSMN1; SMN2RAB9AKMT2ANPC1
SCHEMBL3001893 0.89 AR (0.45) ARSMN1; SMN2RAB9AKMT2ANPC1
SCHEMBL3004385 0.89 AR (0.48) ARSMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3019544 0.88 NPC1 (0.46) ARSMN1; SMN2RAB9AKMT2ANPC1
SCHEMBL3010963 0.88 AR (0.46) ARSMN1; SMN2RAB9AKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885SMN1; SMN2 1/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.